3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
3
Multiple Myeloma
3
Unspecified Adult Solid Tumor, Protocol Specific
2
Solid Tumor
2
Neoplasms
2
Melanoma
2
Colorectal Neoplasms
2
Carcinoma, Renal Cell
2
Refractory or Relapsed Solid Tumors
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms, Plasma Cell
1
Malignant Solid Tumour
1
Lymphangioleiomyomatosis
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Gastrointestinal Neoplasms
1
Estrogen Receptor Positive Breast Cancer
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Bone Metastases
1
Adult Solid Neoplasm
1
Interventions
Oxaliplatin
5
S 1 (combination)
4
Irinotecan
4
pembrolizumab
3
IFL protocol
3
Fluorouracil
3
Bevacizumab
3
amminedichloro(2-methylpyridine)platinum(II)
2
N-(2-fluoro-4-((2-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)carbonylaminopyridin-4-yl)oxy)phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
2
MLN 8237
2
Leucovorin
2
Gemcitabine
2
Folfox protocol
2
Fecal Microbiota Transplantation
2
Drug Therapy
2
Doxorubicin
2
Cyclophosphamide
2
Cisplatin
2
Cetuximab
2
Capecitabine
2
CGX1321
2
ulixertinib
1
tivozanib
1
titanium silicide
1
tislelizumab
1
sodium thiosulfate
1
sacituzumab govitecan
1
remune
1
plecanatide
1
phosphatidyltransferase, Clostridium butyricum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Gastrointestinal Neoplasms
×
Hydroxychloroquine
×
Clear all
NCT04145297
2024-11-18
UTAH
University of Utah
Phase 1
Completed
16 enrolled